

FOR IMMEDIATE RELEASE

AMNEAL LAUNCHES ESCITALOPRAM OXALATE ORAL SOLUTION

Generic equivalent to Lexapro® is first liquid form to market

Bridgewater, NJ (USA), March 14, 2012 – Amneal Pharmaceuticals, LLC today announced the launch of Escitalopram Oxalate Oral Solution in 5 mg/5 mL strength, the first generic in liquid form on the market. Amneal's product is a therapeutically equivalent alternative to Lexapro® (a registered trademark of Forest Laboratories, Inc.). Annual U.S. sales of Lexapro oral solution are \$7.3 million according to December 2011 IMS Health market data.

Escitalopram Oxalate Oral Solution, a prescription drug in the antianxiety and antidepressant therapeutic categories, is available in an 8 fl oz/240 mL bottle that does not require refrigeration. The clear, pale yellow liquid comes in peppermint flavor. Manufactured in Amneal's fully cGMP-compliant Branchburg, NJ plant, this product is now shipping and available through wholesalers-distributors as well as directly to the trade.

"As we continue to grow our liquids portfolio, Escitalopram adds another niche product to our offering," said Chirag Patel, Amneal's president. "Our Branchburg, NJ operation continues to expand production of Amneal's high quality liquids, and our pipeline for this dosage form is strong."

Escitalopram Oxalate Oral Solution joins Amneal's extensive portfolio of superb quality generic drugs in the company's on-line catalog at www.amneal.com. The comprehensive web catalog is designed for easy customer and patient access to essential information, images and literature such as product outserts, prescribing information, labels, patient medication guides, material safety data sheets (MSDS) and high-resolution product photos.

Amneal Pharmaceuticals, LLC, with principal offices in Bridgewater, NJ, is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as "Generic's New Generation," the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline. Efficient ANDA approvals and diverse product acquisitions are key to Amneal's aggressive growth strategy, as is the company's strong commitment to deep customer relationships and maximum value creation. Amneal delivers high-quality products, superior service levels and dynamic value throughout the pharmaceutical industry. For more information, visit www.amneal.com.

###

CONTACT:

Jim Luce
Executive Vice President, Sales & Marketing
Amneal Pharmaceuticals, LLC
Direct: 949-610-8018
Fax: 949-610-8218
E-mail: jim@amneal.com
www.amneal.com
620 Newport Center Drive, 14th Floor
Newport Beach, California 92660